Recombinant multi-species PEX5 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PEX5 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The product of this gene binds to the C-terminal PTS1-type tripeptide peroxisomal targeting signal (SKL-type) and plays an essential role in peroxisomal protein import. Peroxins (PEXs) are proteins that are essential for the assembly of functional peroxisomes. The peroxisome biogenesis disorders (PBDs) are a group of genetically heterogeneous autosomal recessive, lethal diseases characterized by multiple defects in peroxisome function. The peroxisomal biogenesis disorders are a heterogeneous group with at least 14 complementation groups and with more than 1 phenotype being observed in cases falling into particular complementation groups. Although the clinical features of PBD patients vary, cells from all PBD patients exhibit a defect in the import of one or more classes of peroxisomal matrix proteins into the organelle. Defects in this gene are a cause of neonatal adrenoleukodystrophy (NALD), a cause of Zellweger syndrome (ZWS) as well as may be a cause of infantile Refsum disease (IRD). Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Oct 2008]
The Alternative Names of target: ESTM1,PBD2A,PBD2B,PEX5,PTS1 receptor,PTS1-BP,PTS1R,PXR1,PXR1P,Peroxin-5,Peroxisomal C-terminal targeting signal import receptor,Peroxisomal targeting signal 1 receptor,Peroxisome receptor 1,Pex5,Pxr1,RCDP5
Go
to PEX5 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP10777-Ag-1/ GM-Tg-hg-IP10777-Ag-2 | Human PEX5 protein | Human |
| GM-Tg-rg-IP10777-Ag-1/ GM-Tg-rg-IP10777-Ag-2 | Rat PEX5 protein | Rat |
| GM-Tg-mg-IP10777-Ag-1/ GM-Tg-mg-IP10777-Ag-2 | Mouse PEX5 protein | Mouse |
| GM-Tg-cynog-IP10777-Ag-1/ GM-Tg-cynog-IP10777-Ag-2 | Cynomolgus/Rhesus macaque PEX5 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP10777-Ag-1/ GM-Tg-felg-IP10777-Ag-2 | Feline PEX5 protein | Feline |
| GM-Tg-cang-IP10777-Ag-1/ GM-Tg-cang-IP10777-Ag-2 | Canine PEX5 protein | Canine |
| GM-Tg-bovg-IP10777-Ag-1/ GM-Tg-bovg-IP10777-Ag-2 | Bovine PEX5 protein | Bovine |
| GM-Tg-equg-IP10777-Ag-1/ GM-Tg-equg-IP10777-Ag-2 | Equine PEX5 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP10777-Ag-1/ GM-Tg-hg-IP10777-Ag-2;
GM-Tg-rg-IP10777-Ag-1/ GM-Tg-rg-IP10777-Ag-2;
GM-Tg-mg-IP10777-Ag-1/ GM-Tg-mg-IP10777-Ag-2; GM-Tg-cynog-IP10777-Ag-1/ GM-Tg-cynog-IP10777-Ag-2; GM-Tg-felg-IP10777-Ag-1/ GM-Tg-felg-IP10777-Ag-2; GM-Tg-cang-IP10777-Ag-1/ GM-Tg-cang-IP10777-Ag-2; GM-Tg-bovg-IP10777-Ag-1/ GM-Tg-bovg-IP10777-Ag-2; GM-Tg-equg-IP10777-Ag-1/ GM-Tg-equg-IP10777-Ag-2 |
| Products Name | PEX5 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | PEX5 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PEX5 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.